Heart failure with preserved ejection fraction (HFpEF), which currently represents
approximately 50% of heart failure (HF) cases, is common and associated with high …

Doxorubicin-induced cardiotoxicity in childhood cancer survivors is a growing problem. The
population of patients at risk for cardiovascular disease is steadily increasing, as five-year …

Background: The increase in medical complexity among patients hospitalized with heart
failure (HF) may be reflected by an increase in concomitant noncardiovascular …

Aims In heart failure with reduced ejection fraction, drug and device therapy improve
survival. We studied contemporary trends in utilization of evidence‐based therapy and …

Background & Aims It is not clear whether evidence-based recommendations for inpatient
care of patients with cirrhosis are implemented widely or are effective in the community. We …

Aims Cardiac resynchronization therapy (CRT) improves outcomes in heart failure (HF) but
may be underutilized. The reasons are unknown. Methods and results We linked the …

Heart failure (HF) is a clinical syndrome, which is becoming a major public health problem in
recent decades, due to its increasing prevalence, especially in the developed countries …

2672 Circulation June 21, 2016 indication narrowed to include only those with left
bundlebranch block configuration as the driver of the wide QRS, 13 based both on clinical …

Advances in medicine have changed how patients experience the end of life. With longer life
spans, there has also been an increase in years lived with disability. The clustering of …

Natural products have been used for the treatment of human diseases since ancient history.
Over time, due to the lack of precise tools and techniques for the separation, purification, and …